Ioglicic acid
Clinical data | |
---|---|
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.051.320 |
Chemical and physical data | |
Formula | C13H12I3N3O5 |
Molar mass | 670.968 g·mol−1 |
3D model (JSmol) | |
|
Ioglicic acid is a pharmaceutical drug that was used as an iodinated contrast medium for X-ray imaging, in form of its salt meglumine ioglicate. Uses included imaging of the brain,[1] the aorta and femoral arteries,[2] and the urinary system (an examination called intravenous urography).[3]
It is not known to be marketed anywhere in the world in 2021.
References
- ^ Skalpe IO (1983). "Enhancement with water-soluble contrast media in computed tomography of the brain and abdomen. Survey and present state". Acta Radiologica. Supplementum. 366: 72–5. PMID 6382938.
- ^ Wiebe V, Straub H (1983). "Haemodynamic side effects of meglumine ioglicate, meglumine sodium ioxaglate and iohexol in aortofemoral angiography: comparison of a high-osmolar and two low-osmolar radiological contrast media". Fortschritte Auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. Erganzungsband. 118: 78–84. PMID 6139084.
- ^ Baitsch T, Beduhn D, Klink G (1983). "Double blind comparison of ioglicate and iothalamate in intravenous urography". Fortschritte Auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. Erganzungsband. 118: 143–7. PMID 6139069.